The biotech industry saw a strong fundraising quarter, with venture-backed biopharma companies raising $6.8 billion, the largest amount in two years. This marks a positive shift after a downturn in the industry. Additionally, a Pfizer vaccine showed promise in protecting adults aged 18 to 59 against severe illness from respiratory syncytial virus, potentially expanding its approval to a wider population. The vaccine, Abrysvo, is currently approved for adults over 60 and expectant mothers. Overall, these developments indicate positive momentum in the biotech sector, signaling a potential recovery from previous challenges.
Source link
We’re reading about biotech startups, Pfizer’s RSV vaccine
